Skip to main content
. Author manuscript; available in PMC: 2019 May 15.
Published in final edited form as: Bioorg Med Chem. 2018 Apr 6;26(9):2514–2529. doi: 10.1016/j.bmc.2018.04.016

Fig. 11.

Fig. 11

Reversibility studies of the PAR1 antagonists vorapaxar, RWJ-58259, ML161, and RR-90 in the iCa2+ assay. Cells containing antagonists were optionally washed with buffer prior to treatment with the PAR1 agonist TFLLRN-NH2 (5 μM). Vorapaxar and RWJ-58259 were used at 0.316 μM; ML161, CJD125, RR-90 were used at 10 μM.